ArticleEnvironmental monitoring and assessment2020
Monitoring and assessment of the therapeutic impact of metabolites extracted from sponge-associated bacteria screened from Gulf of Mannar, southeast coast of India.
Article in Environmental monitoring and assessment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to assess and monitor the therapeutic potential of antimicrobial metabolites from marine sponge-associated bacteria collected from the southeast coast of India against multidrug-resistant clinical bacterial isolates. Five sponge samples were collected and the metabolite-producing bacteria were screened from the Gulf of Mannar, India, and their antibacterial potential was studied against drug-resistant clinical bacterial isolates obtained from the hospitals. The two metabolite-producing bacteria (IS1 and IS2) were characterized by standard microbiology protocols and 16S rRNA sequencing. The antibacterial metabolites were characterized by liquid chromatography mass spectrometry (LCMS) analysis. The study suggested that marine sponges such as Spheciospongia spp., Haliclona spp., Mycale spp., Tedania spp., and SS-01 were associated with 30 ± 2, 26 ± 2, 23 ± 3, 21 ± 2, and 20 ± 2% of antibacterial metabolite-producing bacteria, respectively. The LCMS analysis of metabolites extracted from IS1 (4,6-dimethyl-2-pyrimidinamine; 4,5-dimethyl-2-propylsilyl-1H-imidazole) and IS2 (caproyl amide, 2-imidazoline) associated with Spheciospongia spp. exhibited significant antibacterial properties against drug-resistant bacteria. IS1 showed antimicrobial potential against the clinical isolates of Proteus spp., and IS2 showed antibacterial potential against isolates of both Proteus mirabilis and Salmonella typhi. IS1 and IS2 were identified by 16S rRNA sequencing and designated as Klebsiella spp. DSCE-bt01 and Pseudomonas spp. DSCE-bt02, respectively. The current study concluded that the assessment and monitoring of novel isolates from sponge-associated bacteria from marine coastal areas probably offer latest breakthrough in curtailing the global antimicrobial resistance and the study of such ecosystems adds value addition to the searching of novel bioactive compounds from terrestrial ecosystems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.